About Chrono Therapeutics Inc.
The Pioneer of Individually - Optimized Transdermal Drug Products
Chrono Therapeutics Inc. (CTI) is a specialty pharmaceutical company focused on the development, manufacture and commercialization of drug-products utilizing our proprietary formulations and transdermal drug delivery platform-ChronoDose™.
CTI’s experienced management team and world-leading class partners merge micro-engineering, pharmacokinetics, formulation, manufacturing and patent expertise to offer patients highly effective, convenient and user-friendly drugs products.
Our initial drug product has been validated through in vivo human clinical studies conducted at the University of Basel and the Basel Hospital. Several of our secondary drug products have been validated in vitro at the University of Basel’s PharmaCenter and CTI’s own in-house laboratories.
This "storehouse" of ChronoDose™ solutions to be made available to the public and the pharmaceutical industry in the near-term represents vast development potential. We believe that ChronoDose™ will improve the lives of young, middle aged and elderly patients across many therapeutic areas.
Recent Developments - 2010
US Patent Granted To Chrono Therapeutics Inc. For Its Chrono-Pharmacological Drug Delivery Systems And Applications.
Patent Protection extends at least to 2025
Release Date: 6/2/2010
Download The PDF
Chrono Therapeutics Inc. receives notification from the European Patent Office that an additional key patent for CHRONODOSE™ has been granted. This new patent grant affirms the novelty of CTI’s technology and believes it will considerably reduce any potential risk to the CTI group.
Chrono Therapeutics Inc. is featured in Transdermal Magazine.
(SEE PAGE 6)